Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Gemma White

Dr. Xuan Ni Tan Awarded a State Government Fellowship

Pirtobrutinib results (formerly known as LOXO-305) published in The Lancet Journal

Trina… ‘Shaving the world from blood cancer!’